Scheimpflug tomographers: Are they precise?

Article

Comparative data demonstrates good agreement between devices

Corneal tomography based on optic technology, Scheimpflug and OCT, has replaced Placido topography more recently. The awareness of the importance of posterior surface and thickness topography has boosted this change.

Regarding Scheimpflug devices, two main hardware configurations compete in this arena: OnlyScheimpflug instruments like Pentacam HR (Oculus, Wetzlar, Germany) and Scheimpflug-Placido machines such as Galilei G2/G4 (Ziemer, Port, Switzerland), Sirius (CSO, Florence, Italy) and TMS-5 (Tomey, Nagoya, Japan).

The need for Placido curvature data comes from the extreme demand for precision in elevation measurements in the centre of the cornea to avoid significant curvature errors. Most Companies defend that Placido information is necessary to improve accuracy and precision. However, the Pentacam HR has maintained its only-Sheimpflug configuration over the years (first marketed in 2001) relying on its eyetracking and reconstruction algorithms. Whereas, the Galilei claims a higher precision in thickness measurement as a result of its two opposite rotating cameras, self-compensating for any decentration error.

There is no gold-standard in corneal curvature measurement to test the accuracy of any device in a certain cornea. So, accepting all of them are accurate as they can correctly measure test eyes, precision and agreement testing is the way to analyse and compare these instruments. Precision will affect the usefulness of a topographer in issues like determining keratoconus progression, IOL power calculations, calculating customized ablation patterns and so on.

We have performed a prospective randomized comparison of the Galilei G2 (software 5.2.1) and the Pentacam HR (software 1.7) by means of 3 consecutive measurements by 2 expert explorers on 35 eyes of 35 healthy subjects. Intraobserver variability defines repeatability and interobserver variability defines reproducibility of the measument. The basic statistic is the within-subject standard deviation (Sw) that allows calculation of the error Gaussian bell.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.